How does Mounjaro work? Tirzepatide and the science of GIP and GLP-1
Mounjaro contains tirzepatide. Learn how one molecule activates two hormone receptors, what this changes in the body and what to ask a prescriber.
Health / The Compound journalPhoto: Raimond Spekking · Wikimedia Commons · CC BY-SA 4.0 · cropped · Illustrative image.
Mounjaro contains tirzepatide, a medicine that activates two hormone receptors called GIP and GLP-1. It is given by weekly injection. Its EU authorisation covers type 2 diabetes and weight management in eligible adults, with criteria and prescribing instructions set out in the product information. EMA Mounjaro overview · EMA product information
The Science Behind the Drug
GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both are hormones released by the gut in response to food. They are called incretins because they help the body release insulin when glucose is elevated. Tirzepatide is a single molecule that activates the receptors for both hormones. EMA product information, section 5.1
Activation of these receptors affects insulin release and blood glucose. Tirzepatide also reduces appetite and food intake. The receptors are found in areas of the brain involved in appetite regulation, among other tissues. Clinical trials test the effects of the whole medicine, so the diagram shows its targets rather than how much each receptor contributes to the overall result. EMA product information, section 5.1
How does tirzepatide compare with semaglutide?
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and GIP receptors. That distinction explains why tirzepatide is described as a dual GIP and GLP-1 receptor agonist. To compare clinical outcomes, look at studies that specify the dose, population and outcome measured. EMA: Mounjaro · EMA: Wegovy
What should you discuss with your prescriber?
Nausea, diarrhoea and vomiting can occur. Severe, persistent abdominal pain needs urgent medical advice as it can be a sign of pancreatitis. Tell your prescriber if you use insulin or a sulfonylurea, have significant digestive symptoms, or are pregnant or planning a pregnancy. Tell your procedure team if you are due to receive general anaesthesia or deep sedation. EMA Mounjaro product information and leaflet
What two receptor targets can and cannot tell you
GIP and GLP-1 are signals released after food intake. Tirzepatide can activate both receptors. That makes its mechanism different from semaglutide’s, but receptor counts cannot predict how much weight any person will lose or how they will tolerate treatment. Outcomes have to be read from studies in the relevant population. A study in type 2 diabetes and a weight-management study may measure different outcomes and use different background treatment. EMA Mounjaro information
Which information helps when a prescriber is reviewing you?
Bring why it was started, the exact product, any changes to the prescription and the timing of appetite or gastrointestinal symptoms. If you take insulin or another drug that can lower glucose, ask how the treatment plan deals with low readings. Tell the team about persistent vomiting or difficulty drinking, and about upcoming procedures involving deep sedation or anaesthesia. Severe persistent abdominal pain warrants urgent assessment. EMA Mounjaro information
If comparing with another product or changing treatment, check whether the plan refers to semaglutide or liraglutide. These products have their own formulations, schedules and review points.
Read more on Compound Health
- Irish costs for Mounjaro, Wegovy and Ozempic and Irish reimbursement and medical card coverage
- GLP-1 side effects and when to get help and what happens after stopping treatment
- How liraglutide works
Cover photograph and cropped versions licensed under CC BY-SA 4.0.


